IONS logo

Ionis Pharmaceuticals Inc. (IONS)$75.56

Market Cap: 5.35 BCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Ionis Pharmaceuticals Inc. (IONS).

HEALTHCARE
BIOTECHNOLOGY
DCF ready

Valuation

-21.2x

EV/FCF, N/A FCF yield

Quality

-16.6%

ROIC, -33.9% FCF margin

Growth

5.3%

5Y sales (revenue) CAGR

Balance sheet

3.7x

Debt/equity, 3.8x current ratio

Superinvestors

1

Top: Tweedy Browne Co. (13.6%)

Strengths to research

  • 10 annual periods are available for trend analysis.

Watchouts

  • Free cash flow margin is negative at -33.9%.
  • Debt/equity is high at 3.7x.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for IONS.

Grade F
12
/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
IONS
Target
Ionis Pharmaceuticals Inc.$5.4B-31.7x-21.2x-16.6%5.3%-33.9%N/AN/AN/A
AXSMAxsome Therapeutics Inc.$5.7B-64.1x-57.1x-207.5%N/A-14.7%N/AN/AN/A
LEGNLegend Biotech Corp.$6.1BN/AN/AN/AN/AN/AN/AN/AN/A
PCVXVaxcyte Inc.$4.4B-8.4x-6.3x-0.0%N/AN/AN/AN/AN/A
BBIOBridgeBio Pharma Inc.$7.3B-18.3x-19.5xN/A127.4%-89.0%N/AN/AN/A
HALOHalozyme Therapeutics$7.5B26.7x14.7x14.5%39.2%46.2%N/A4.2xN/A
TECHBio-Techne Corp.$7.9B104.8x30.1x3.8%10.5%21.0%64.8%-0.8xN/A
ROIVRoivant Sciences Ltd$8.3B-55.5x-9.0x-6.6%-19.1%-9183.5%N/AN/AN/A
MRNAModerna, Inc.$10.8B-6.5x-4.0x-32.6%19.3%-106.2%N/AN/AN/A

Financial Charts

No financial data available for IONS (annual).

1 superinvestors own IONS

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
Tweedy Browne Co.

Tweedy Browne Value Fund

2,275,625$171M13.57%0.0%